Aarti Drugs Ltd latest updates centre on its FY26

latest updates centre on its FY26 full-year results, a management transition, and corporate actions ahead of its 41st AGM. For the year ended 31 March 2026, the company reported consolidated revenue of ₹2,568 crore, up 6.8% year on year, and consolidated PAT of ₹195 crore, up 16%, driven by new facility commercialisation and a higher share of regulated-market sales, even as raw-material cost volatility remained a concern. In Q1 FY27 (June 2026), consolidated revenue grew 19% to ₹703.6 crore and EBITDA rose 30% to ₹96.9 crore with margin expanding to 13.8%, while net profit dipped 7.1% to ₹50.1 crore due to a prior-year tax-refund base effect. The company has announced a leadership change effective October 2026, with Rashesh C. Gogri taking over as Chairman and Adhish P. Patil as Managing Director, as part of succession planning. The board also approved a Performance Stock Option Plan 2026 for up to 8 lakh options, subject to shareholder approval. Aarti Drugs will hold its 41st AGM on 26 September 2026 via video conference, with the record date for voting eligibility on 19 September and remote e-voting from 23–25 September.